Evonik stock faces BASF price discipline ahead of November 3 results
Published on 10/30/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal Conditions Meet an Earnings Test
- BASF CEO Markus Kamieth said a combination with Evonik would require value creation for BASF shareholders.
- The reported 24-euro approach remains unconfirmed and is not a binding public offer.
- Evonik's third-quarter report on November 3 is the next operating checkpoint for investors.
Evonik stock faced a renewed valuation hurdle on Friday, October 30, after BASF stressed that any combination would have to create value for its own shareholders. Reuters reported the comments on October 28 following BASF's quarterly results.
Price Discipline Limits Deal Expectations
BASF CEO Markus Kamieth said the company would pursue a potential transaction only if it were value accretive for BASF shareholders. He also described a combination as an option rather than a necessity, reinforcing the condition attached to the reported approach.
People close to the talks told Reuters that BASF had raised its reported approach to 24 euros per Evonik share, implying an equity value of 11.18 billion euros. Evonik and BASF have not confirmed a formal public offer, so the reported figure remains an indication rather than an agreed transaction term.
What Changed Since the Earlier Report
The latest Lang & Schwarz quote was 20.83 euros at 16:34 CET on Friday, October 30, 2026. That was 1.14 percent below the 21.07-euro quote in the earlier Ad Hoc News report from 10:47 CET the same day.
The later intraday move is a separate comparison from a same-session Xetra closing-price measure. It leaves the share price below the reported approach and keeps the market focused on both the credibility of the potential deal and Evonik's standalone earnings performance.
November Report Sets Next Test
Evonik's investor-relations calendar lists November 3, 2026, for publication of the third-quarter report. The release will give investors a fresh benchmark for operating performance while negotiations around a possible combination remain unresolved. Evonik's investor-relations page also lists the fourth-quarter 2026 report for March 4, 2027.
Investors should distinguish a reported approach from a binding offer. A formal offer, agreed terms and the required shareholder and regulatory steps would still be needed before the reported price could become an actionable transaction reference.
German equities remain sensitive to industrial earnings, takeover speculation and changes in the outlook for European chemicals; see current DAX market coverage.
For the real-time quote of Evonik stock, investors can follow the latest Lang & Schwarz price.
More news and analyses on Evonik stock.
Evonik AG
- ISIN: DE000EVNK013
- Lang & Schwarz quote: 20.83 euros on October 30, 2026, at 16:34 CET
- Change since earlier Ad Hoc News report: Down 1.14 percent from 21.07 euros at 10:47 CET
- Next report: Third-quarter 2026 results on November 3, 2026
